Molecular Partners Ag (MOLN) — 6-K Filings

All 6-K filings from Molecular Partners Ag. Browse 21 Foreign Current Report reports with AI-powered summaries and risk analysis.

6-K Filings (21)

Molecular Partners AG Files 6-K Report — Mar 30, 2026 Risk: low
Molecular Partners AG filed a 6-K report on March 30, 2026, for the period ending March 31, 2026. The filing includes a press release (EX-99.1) and other docume
6-K Filing — Dec 8, 2025
6-K Filing — Nov 12, 2025
Molecular Partners AG Files Q3 2025 Financials — Oct 30, 2025 Risk: low
Molecular Partners AG filed a Form 6-K on October 30, 2025, to furnish a press release and unaudited condensed consolidated interim financial statements for the
Molecular Partners AG Files 6-K with H1 2025 Financials — Aug 25, 2025 Risk: low
Molecular Partners AG filed a 6-K report on August 25, 2025, for the period ending June 30, 2025. The filing includes financial data for the first half of 2025
Molecular Partners AG Files 6-K with Press Release — Jun 12, 2025 Risk: low
Molecular Partners AG filed a Form 6-K on June 12, 2025, to furnish a press release issued on June 10, 2025. This filing incorporates the press release by refer
Molecular Partners AG Files 6-K with Financials and Press Release — May 15, 2025 Risk: low
Molecular Partners AG filed a Form 6-K on May 15, 2025, to furnish a press release and unaudited condensed consolidated interim financial statements for the thr
Molecular Partners AG Reports 2025 AGM Results — Apr 29, 2025 Risk: low
Molecular Partners AG held its 2025 Annual General Meeting on April 16, 2025, in Schlieren, Switzerland. The results of this meeting are now available on the co
Molecular Partners AG Files March 2025 6-K Report — Mar 6, 2025 Risk: low
Molecular Partners AG, a Swiss biotechnology company, filed a Form 6-K on March 6, 2025. This report is for the month of March 2025 and indicates the company fi
Molecular Partners AG Files Routine 6-K Disclosure — Jan 13, 2025 Risk: low
Molecular Partners AG filed a Form 6-K on January 13, 2025, to report its status as a foreign private issuer. The company, incorporated in Switzerland, is requi
Molecular Partners AG Files 6-K with Financials — Oct 31, 2024 Risk: low
Molecular Partners AG filed a Form 6-K on October 31, 2024, to furnish a press release and unaudited condensed consolidated interim financial statements for the
Molecular Partners AG Announces Underwritten Offering — Oct 28, 2024 Risk: medium
On October 24, 2024, Molecular Partners AG entered into an underwriting agreement with Leerink Partners LLC and TD Securities (USA) LLC for an underwritten regi
Molecular Partners AG: Novartis Deal & MP0712 Data Presented — Oct 22, 2024 Risk: medium
On October 22, 2024, Molecular Partners AG announced the presentation of preclinical data for MP0712, a Radio-DARPin Therapeutic (RDT), at the European Associat
Molecular Partners AG Files 6-K for Q2 2024 — Aug 26, 2024 Risk: low
Molecular Partners AG filed a 6-K report for the period ending June 30, 2024. The filing provides financial information and details related to the company's ope
Molecular Partners AG Files 6-K, Incorporates Press Release — Jun 14, 2024 Risk: low
On June 14, 2024, Molecular Partners AG filed a Form 6-K to report the issuance of a press release. This press release is incorporated by reference into their e
Molecular Partners AG Files 6-K Announcing Press Release — Jun 11, 2024 Risk: low
On June 11, 2024, Molecular Partners AG filed a Form 6-K, announcing the issuance of a press release dated the same day. This press release is attached as Exhib
Molecular Partners AG Files 6-K with June 1 Press Release — Jun 3, 2024 Risk: low
Molecular Partners AG filed a Form 6-K on June 3, 2024, to report a press release issued on June 1, 2024. The filing incorporates this press release by referenc
Molecular Partners AG Files 6-K with Q1 2024 Financials — May 16, 2024 Risk: low
Molecular Partners AG filed a Form 6-K on May 16, 2024, to furnish a press release and unaudited condensed consolidated interim financial statements for the thr
Molecular Partners AG Files 6-K, Attaches Press Release — Mar 26, 2024 Risk: low
Molecular Partners AG announced on March 26, 2024, that it has issued a press release. This press release is attached as Exhibit 99.1 to the Form 6-K filing and
Molecular Partners Updates on MP0533, RDT, & New Switch-DARPin Program — Jan 8, 2024
Molecular Partners AG announced updates at the 42nd Annual J.P. Morgan Healthcare Conference on January 7, 2024. Key updates include their tetra-specific T-cell
Molecular Partners & Orano Med Partner on Radio-DARPin Cancer Therapies — Jan 5, 2024
Molecular Partners AG announced a co-development agreement with Orano Med on January 5, 2024, to create new radio-DARPin therapies for cancer. This collaboratio

Popular Companies

AAPL · TSLA · MSFT · AMZN · GOOGL · META · NVDA · JPM · BRK-B · V · JNJ · UNH · XOM · WMT · MA · PG · HD · DIS · BAC · NFLX